ERBB2 amplification is found with greater frequency in mucinous ovarian carcinoma than in mucinous borderline ovarian tumors, suggesting it is a key genomic event in tumor progression (Mackenzie et al., 2015, Cheasley et al., 2019). The gene discussed is ERBB2; the disease is ovarian mucinous adenocarcinoma.